PC
ACAD icon

Pier Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Pier Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-159,675
Closed -$5.69M – 113
2015
Q4 		$5.69M Buy
+159,675
New +$5.63M 0.98% 62

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Pier Capital's ACAD Position: Q1 2016 in Review

Pier Capital sold out of Acadia Pharmaceuticals (ACAD) in Q1 2016, closing a stake of 159,675 shares — an estimated $5.69M sold.

Pier Capital first reported a position in ACAD in Q4 2015 and held it in 1 quarter. The position peaked at $5.69M in Q4 2015. 213 funds tracked by Wall St. Rank hold ACAD as of Q1 2016.

  • Pier Capital reported no remaining Acadia Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Pier Capital sold 159,675 Acadia Pharmaceuticals shares in Q1 2016, an estimated $5.69M.
  • Pier Capital first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Pier Capital's Acadia Pharmaceuticals position peaked at $5.69M in Q4 2015.
  • 213 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2016.

Based on Pier Capital's 13F filing for Q1 2016, filed 5 May 2016.